Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
Mon Compte
No element in selection

Favoris
Établissements de santé
Contact Abonnez-vous aux actualités

1 result

Active substance : azacitidine
Topics : Blood and lymphatic diseases
Topics : Diagnostic and therapeutic techniques
Topics : Diseases and conditions

Topic

Diagnostic and therapeutic techniques (1)
Plus ...
- Drug therapy (1)
Diseases and conditions (1)
Plus ...
- Blood and lymphatic diseases (1)
- Plus ...
  - Hematologic cancers (1)

Drugs, devices and medical acts (1)
Plus ...
- Medicine (1)

Français (1)

Active substance

azacitidine (1)

More filter Other Filter Icon

Other Filter Icon

Search Export

Drugs, devices and medical acts - 1 result

VIDAZA (azacitidine), antimétabolite

Medicine - Posted on 4/10/2017 - Mis à jour le 12/6/2019

Add to my selection

Follow us :

Advancing quality in the fields of health and social care services

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

mcVyxz1u7HnTV4xC